
Alopecia Associated with Antibody-Drug Conjugates and Impact of Cold Caps For Patients with Breast Cancer

Samer Alkassis MD[1], Lisa Zhang MD[1], Eric Yang[1], Marla Lipsyc-Sharf MD[1], Kelly McCann MD PhD[1], Nicholas McAndrew MD MSCE[1], Aashini Master MD[1], Julia LaBarbera NP, Mina Sedrak MD MS[1], Nicolaos Palaskas MD PhD[1], Kristie Greene[1], Madelaine Kuiper NP[1], John Glaspy MD MPH[1], David Elashoff PhD[1], Rena Callahan MD[1], Aditya Bardia MD MPH[1] [1]UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA


Abstract # 1371; Dec 10, 2025

Introduction

- ADC-related alopecia is under characterized, in the context of scalp cooling and pre-existing alopecia.
- This study evaluates the incidence of alopecia with T-DXd and SG and examines the potential protective effect of cold cap usage.





Methods




Cohort Overview


	All Patients (n = 103)	T-DXd (n = 39)	SG (n = 38)	Both Agents (n = 26)	P - Value
Age at Primary Diagnosis, Median (Range)	54 (26 - 80)	53 (29 - 80)	54 (26 - 76)	58 (31 - 76)	0.4184
Sex (Female)	102	38	38	26	
Race, n (%)					0.0449
White or Caucasian	34 (33.01%)	7 (17.95%)	17 (44.74%)	10 (38.46%)	
Asian	13 (12.62%)	7 (17.95%)	6 (15.79%)	0 (0.00%)	
Black or African American	3 (2.91%)	0 (0.00%)	1 (2.63%)	2 (7.69%)	
Unknown	18 (17.48%)	7 (17.95%)	6 (15.79%)	5 (19.23%)	
Other	35 (33.98)	18 (46.15%)	8 (21.05%)	9 (34.62%)	
Ethnicity, n (%)					0.6227
Hispanic or Latino	11 (10.68%)	5 (12.82%)	4 (10.53%)	2 (7.69%)	
Not Hispanic or Latino	77 (74.76%)	31 (79.49%)	27 (71.05%)	19 (73.08%)	
Unknown	15 (14.56%)	3 (7.69%)	7 (18.42%)	5 (19.23%)	
Duration of ADC Therapy, Median (Range, Months)	6.30 (0.00 – 52.5)	8.71 (0.00 – 49.8)	3.45 (0.00 – 39.6)	8.74 (2.30 – 29.7)	**<0.01**





Results





Conclusions

- Alopecia is a common treatment-related toxicity among MBC patients receiving T-DXd or SG, affecting nearly one half of patients without baseline hair loss.
- The remaining patients lacked clear documentation of alopecia during ADC treatment, which may reflect underreporting of this adverse event.
- Scalp cooling during ADC therapy was infrequent and appeared to offer limited protection against ADC-related alopecia.

Contact
Samer Alkassis, UCLA
Email: salkassis@mednet.ucla.edu

This presentation is the intellectual property of the author/presenter. Contact them salkassis@mednet.ucla.edu for permission to reprint and/or distribute.